Skip to main content
SpringerLink
Log in

Depression in Parkinson’s Disease: An Update

  • Chapter
  • First Online:
Parkinson’s Disease and Nonmotor Dysfunction

Part of the book series: Current Clinical Neurology ((CCNEU))

  • 2783 Accesses

Abstract

Depression is the most common psychological disturbance that affects people with Parkinson’s disease (PD). Despite an increasing amount of research devoted to this topic, uncertainty still exists concerning many aspects of depression in PD. Significant questions remain regarding some very basic issues, including how best to diagnose depression in PD, how frequently depression complicates PD, the risk factors for developing depression, and how best to treat depression. This chapter provides a current perspective on what is known about depression in PD, reviewing its epidemiology, etiology, and treatment. Rather than providing a comprehensive overview, the focus here is on updating the major themes of research in this field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kuhn W, Heye N, Muller TH, et al. The motor ­performance test series in Parkinson’s disease is influenced by depression. J Neural Transm. 1996;103:349–54.

    PubMed  CAS  Google Scholar 

  2. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69:308–12.

    PubMed  CAS  Google Scholar 

  3. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc. 2004;52:784–8.

    PubMed  Google Scholar 

  4. Chen P, Kales HC, Weintraub D, et al. Depression in veterans with Parkinson’s disease: frequency, co-morbidity, and healthcare utilization. Int J Geriatr Psychiatry. 2007;22:543–8.

    PubMed  CAS  Google Scholar 

  5. Reijnders JS, Uwe E, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23:183–9.

    PubMed  Google Scholar 

  6. Leentjens AFG. Depression in Parkinson’s disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol. 2004;17:120–6.

    PubMed  Google Scholar 

  7. Cummings JL. Depression and Parkinson’s disease: a review. Am J Psychiatry. 1992;149:443–54.

    PubMed  CAS  Google Scholar 

  8. Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, Mellow AM. Antidepressant treatment of veterans with Parkinson’s disease and depression. J Geriatr Psychiatry Neurol. 2007;20(3):161–5.

    PubMed  Google Scholar 

  9. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson’s disease. A community-based study. Arch Neurol. 1996;53:175–9.

    PubMed  CAS  Google Scholar 

  10. Weintraub D. Diagnosing and treating depression in patients with Parkinson’s disease. Psychiatric Ann. 2004;34:299–304.

    Google Scholar 

  11. Veazy C, Aki SOE, Cook KF, Lai EC, Kunik ME. Prevalence and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2005;17:310–23.

    Google Scholar 

  12. Goldberg DP, William P. A user’s guide to the General Health Questionnaire. Windsor: NFER-Nelson; 1988.

    Google Scholar 

  13. Hantz P, Caradoc-Davies G, Caradoc-Davies T, et al. Depression in Parkinson’s disease. Am J Psychiatry. 1994;151:1010–4.

    PubMed  CAS  Google Scholar 

  14. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.

    PubMed  CAS  Google Scholar 

  15. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson’s disease. J Nerv Ment Dis. 1990;178:27–31.

    PubMed  CAS  Google Scholar 

  16. Celesia GG, Wanamaker WM. Psychiatric disturbances in Parkinson’s disease. Dis Nerv Syst. 1976;37:123–5.

    PubMed  CAS  Google Scholar 

  17. Brown R, Jahanshahi M. Depression in Parkinson’s disease: a psychosocial viewpoint. Adv Neurol. 1995;65:61–84.

    PubMed  CAS  Google Scholar 

  18. Starkstein SE, Berthier ML, Bolduc PL, et al. Depression in patients with early versus late onset Parkinson’s disease. Neurology. 1989;39:1441–5.

    PubMed  CAS  Google Scholar 

  19. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry. 1986;49:381–9.

    PubMed  CAS  Google Scholar 

  20. Brown RC, MacCarthy B. Psychiatric morbidity in patients with Parkinson’s disease. Psychol Med. 1990;20:77–87.

    PubMed  CAS  Google Scholar 

  21. Huber SJ, Paulson GW, Shuttleworth EC. Depression in Parkinson’s disease. Neuropsychiatry Neuropsychol Behav Neurol. 1988;1:47–51.

    Google Scholar 

  22. Jankovic J, McDermott M, Carter J, et al. Parkinson Study Group. Variable expression of Parkinson’s disease: a baseline analysis of the DATATOP cohort. Neurology. 1990;40:1529–34.

    Google Scholar 

  23. Brown GL, Wilson WP. Parkinsonism and depression. South Med J. 1972;65:540–5.

    PubMed  CAS  Google Scholar 

  24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.

    Google Scholar 

  25. Leentjens AFG, Marinus J, Van Hilten JJ, et al. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson’s disease: a discriminant analytic approach. J Neuropsychiatry Clin Neurosci. 2003;15:74–7.

    PubMed  CAS  Google Scholar 

  26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.

    PubMed  CAS  Google Scholar 

  27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.

    PubMed  CAS  Google Scholar 

  28. Marsh L, McDonald WM, Cummings J, Ravina B, the NINDS/NIMH Work Group on Depression and Parkinson’s Disease. Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord. 2006;21:148–58.

    PubMed  Google Scholar 

  29. Burke WJ, Rubin EH, Morris J, Berg L. Symptoms of depression in dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 1988;2:356–62.

    PubMed  CAS  Google Scholar 

  30. Gonera EG, van’t Hof M, Berger HJ, et al. Symptoms and duration of the prodromal phase in Parkinson’s disease. Mov Disord. 1997;12:871–6.

    PubMed  CAS  Google Scholar 

  31. Schuurman AG, van den Akker M, Ensinck K, et al. Increased risk of Parkinson’s disease after depression: a retrospective cohort study. Neurology. 2002;58:1501–4.

    PubMed  CAS  Google Scholar 

  32. Leentjens AFG, Van den Akker M, Metsemakers JFM, Lousberg R, Verhey FRJ. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord. 2003;18:414–8.

    PubMed  Google Scholar 

  33. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson’s disease. Acta Neurol Scand. 2006;113:211–20.

    PubMed  CAS  Google Scholar 

  34. Krishnan KR, Delong M, Kraemer H, et al. Comorbidity of depression with other medical diseases in the elderly. Biol Psychiatry. 2002;52:559–88.

    PubMed  Google Scholar 

  35. Nilsson FM, Kessing LV, Sorensen TM, et al. Major depressive disorder in Parkinson’s disease: a register-based study. Acta Psychiatr Scand. 2002;106:202–11.

    PubMed  Google Scholar 

  36. Leentjens AFG, Lousberg R, Verhey FJR. Markers for depression in Parkinson’s disease. Acta Psychiatr Scand. 2002;106:196–201.

    PubMed  CAS  Google Scholar 

  37. MacCarthy B, Brown RG. Psychosocial factors in Parkinson’s disease. Br J Clin Psychol. 1989;28:41–52.

    PubMed  Google Scholar 

  38. Oertel WH, Hoglinger GU, Caraceni T, et al. Depression in Parkinson’s disease. Adv Neurol. 2001;86:373–83.

    PubMed  CAS  Google Scholar 

  39. Mayeux R, Stern Y, Cote L, Williams BW. Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology. 1984;34(5):642–6.

    PubMed  CAS  Google Scholar 

  40. Mayeux R. The “serotonergic hypothesis” for depression in Parkinson’s disease. Adv Neurol. 1990;53:163–6.

    PubMed  CAS  Google Scholar 

  41. Fibiger HC. The neurobiological substrates of depression in Parkinson’s disease: a hypothesis. Can J Neurol Sci. 1984;11:105–7.

    PubMed  CAS  Google Scholar 

  42. Price KS, Farley IJ, Hornykiewicz O. Neurochemistry of Parkinson’s disease: relation between striatal and limbic dopamine. Adv Biochem Psychopharmacol. 1978;19:293–300.

    PubMed  CAS  Google Scholar 

  43. Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson’s disease? Neurology. 1980;30:1326–30.

    PubMed  CAS  Google Scholar 

  44. Baxter Jr LR, Schwartz JM, Phelps ME, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry. 1989;46:243–50.

    PubMed  CAS  Google Scholar 

  45. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson Diseases. Arch Neurol. 2003;60:337–41.

    PubMed  Google Scholar 

  46. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128:1314–22.

    PubMed  Google Scholar 

  47. Bejjani BP, Damier P, Arnulf I, et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med. 1999;340:1476–80.

    PubMed  CAS  Google Scholar 

  48. Alexopoulos G, Kiosses D, Klimstra S, Kalayam B, Bruce M. Clinical presentation of the “depression-executive dysfunction syndrome” of late life. Am J Geriatr Psychiatry. 2002;10:98–106.

    PubMed  Google Scholar 

  49. Des Rosiers G. Primary or depressive dementia: mental status screening. Int J Neurosci. 1992;64:33–67.

    CAS  Google Scholar 

  50. LaRue A. Aging and neuropsychological assessment. New York: Plenum; 1992. p. 259–89.

    Google Scholar 

  51. Rosenstein LD. Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: a summary of the literature of the early 1990s. Neuropsychol Rev. 1998;8:109–67.

    PubMed  CAS  Google Scholar 

  52. Mayeux R. Depression in the patient with Parkinson’s disease. J Clin Psychiatry. 1990;51(suppl):20–3.

    PubMed  Google Scholar 

  53. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson’s disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115–38.

    PubMed  CAS  Google Scholar 

  54. Barone P, Scarzella L, Marconi R, et al. For the Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national ­multicenter parallel-group randomized study. J Neurol. 2006;253:601–7.

    Google Scholar 

  55. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10:399–406.

    PubMed  CAS  Google Scholar 

  56. Leentjens AFG, Koester J, Fruh B, Shephard DTS, Barone P, Houben JJG. The effect of pramipexole on mood and motivational symptoms in Parkinson’s disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009;31:89–98.

    PubMed  CAS  Google Scholar 

  57. Jouvent R, Abensour P, Bonnett AM, et al. Antiparkinsonian and antidepressant effects of high doses of bromocriptine: an independent comparison. J Affect Disord. 1983;5:141–5.

    PubMed  CAS  Google Scholar 

  58. Allain H, Pollak P, Neukirch HC, et al. Symptomatic effect of selegiline in de novo parkinsonian patients: the French selegiline multicenter trial. Mov Disord. 1993;8 Suppl 1:36–40.

    Google Scholar 

  59. Steur ENHJ, Ballering LAP. Combined and selective monamine oxidase inhibition in the treatment of depression in Parkinson’s disease. In: Stern GM, editor. Parkinson’s disease: advances in neurology, vol. 80. Philadelphia, PA: Lippincott Williams & Wilkins; 1999. p. 505–8.

    Google Scholar 

  60. Thobois S, Mertens P, Guenot M, et al. Subthalamic nucleus stimulation in Parkinson’s disease: clinical evaluation of 18 patients. J Neurol. 2002;249:529–34.

    PubMed  CAS  Google Scholar 

  61. Krack P, Batir A, Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med. 2003;349:1925–34.

    PubMed  CAS  Google Scholar 

  62. Herzog J, Volkmann J, Krack P, et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson’s disease. Mov Disord. 2003;18:1332–7.

    PubMed  Google Scholar 

  63. Martinez-Martin P, Valldeoriola F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson’s disease. Mov Disord. 2002;17:372–7.

    PubMed  Google Scholar 

  64. Smeding HMM, Speelman JD, Koning-Haanstra M, Schuurman PR, Nijssen P, Van Laar T, Schmand B. Neuropsychological effects of bilateral STN stimulation in Parkinson’s disease: a controlled study. Neurology. 2006;66:1830–6.

    PubMed  CAS  Google Scholar 

  65. Deuschl G, Schade-Brittinger C, Krack P, et al. For the German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355:896–908.

    Google Scholar 

  66. Funkiewiez A, Ardouin C, Krack P, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson’s disease. Mov Disord. 2003;18:524–30.

    PubMed  Google Scholar 

  67. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain. 2008;131:2720–8.

    PubMed  Google Scholar 

  68. Soulas T, Gurruchaga JM, Palfi S, Cesaro P, Nguyen JP, Fenelon G. Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2008;79:952–4.

    PubMed  CAS  Google Scholar 

  69. Houeto JL, Mesnage V, Mallet L, et al. Behavioral disorders, Parkinson’s disease and subthalamic ­stimulation. J Neurol Neurosurg Psychiatry. 2002;72:701–7.

    PubMed  CAS  Google Scholar 

  70. Burkhard PR, Vingerhoets FJG, Berney A, Bogousslavsky J, Villemure JG, Ghika J. Suicide after successful deep brain stimulation for movement disorders. Neurology. 2004;63:2170–2.

    PubMed  CAS  Google Scholar 

  71. Berney A, Vingerhoets F, Perrin A, et al. Effect on mood of subthalamic DBS for Parkinson’s disease: a consecutive series of 24 patients. Neurology. 2002;59:1427–9.

    PubMed  CAS  Google Scholar 

  72. Doshi PK, Chhaya N, Bhatt MH. Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson’s disease. Mov Disord. 2002;17:1084–100.

    PubMed  Google Scholar 

  73. Romito LM, Raja M, Daniele A, et al. Transient mania with hypersexuality after surgery for high-frequency stimulation of the subthalamic nucleus in Parkinson’s disease. Mov Disord. 2002;17:1371–4.

    PubMed  Google Scholar 

  74. Kulisevsky J, Berthier ML, Gironell A, et al. Mania following deep brain stimulation for Parkinson’s disease. Neurology. 2002;59:1421–4.

    PubMed  CAS  Google Scholar 

  75. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomized multicentre study. Lancet Neurol. 2008;7:605–14.

    PubMed  Google Scholar 

  76. Myslobodsky M, Lalonde FM, Hicks L. Are patients with Parkinson’s disease suicidal? J Geriatr Psychiatry Neurol. 2001;14:120–4.

    PubMed  CAS  Google Scholar 

  77. Voon V, Krack P, Lang A, et al. Factors associated with suicide risk following STN DBS for Parkinson’s disease. Mov Disord. 2006;21 Suppl 15:S691.

    Google Scholar 

  78. Schlaepfer TE, Fins JJ. Deep brain stimulation and the neuroethics of responsible publishing, when one is not enough. JAMA. 2010;303:775–6.

    PubMed  CAS  Google Scholar 

  79. Agid Y, Schupback M, Gargiulo M, et al. Neurosurgery in Parkinson’s disease: the doctor is happy, the patient less so? J Neural Transm Suppl. 2006;70:409–14.

    PubMed  Google Scholar 

  80. Voon V, Saint-Cyr J, Lozano AM, Moro E, Poon YY, Lang AE. Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. J Neurosurg. 2005;103:246–51.

    PubMed  Google Scholar 

  81. Mendis T, Suchowersky O, Lang A, Gauthier S. Management of Parkinson’s disease: a review of current and new therapies. Can J Neurol Sci. 1999;26:89–103.

    PubMed  CAS  Google Scholar 

  82. Lieberman A. Managing the neuropsychiatric symptoms of Parkinson’s disease. Neurology. 1998;50:S33–8.

    PubMed  CAS  Google Scholar 

  83. Poewe W, Seppi K. Treatment options for depression and psychosis in Parkinson’s disease. J Neurol. 2001;248 Suppl 3:III12–21.

    PubMed  Google Scholar 

  84. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson’s disease (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology. 2006;66:996–1002.

    PubMed  CAS  Google Scholar 

  85. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov Disord. 2005;20:1161–9.

    PubMed  Google Scholar 

  86. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72:886–92.

    PubMed  CAS  Google Scholar 

  87. Leentjens AFG, Vreeling FW, Luijckx GJ, Verhey FRJ. SSRIs in the treatment of depression in Parkinson’s disease. Int J Geriatr Psychiatry. 2003;18:552–4.

    PubMed  CAS  Google Scholar 

  88. Menza M, Marin H, Kaufman K, Mark M, Lauritano M. Citalopram treatment of depression in Parkinson’s disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci. 2004;16:315–9.

    PubMed  CAS  Google Scholar 

  89. Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Mov Disord. 2006;21:1119–22.

    PubMed  Google Scholar 

  90. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology. 2000;55:1216–8.

    PubMed  CAS  Google Scholar 

  91. Tesei A, Antonini A, Canesi M, et al. Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord. 2000;15:986–9.

    PubMed  CAS  Google Scholar 

  92. Dell’Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol. 2001;24:221–7.

    PubMed  Google Scholar 

  93. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord. 1997;12:756–9.

    PubMed  CAS  Google Scholar 

  94. Weintraub D, Taraborelli D, Morales K, Duda JE, Katz IR, Stern MB. Escitalopram for major depression in Parkinson’s disease: an open-label, flexible-dosage study. J Neuropsychiatry Clin Neurosci. 2006;18:377–83.

    PubMed  CAS  Google Scholar 

  95. Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson’s disease treated with citalopram. Nord J Psychiatry. 1998;52:163–9.

    Google Scholar 

  96. Andersen J, Aabro E, Gullmann N, et al. Antidepressive treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with l-dopa. Acta Neurol Scand. 1980;62:210–9.

    PubMed  CAS  Google Scholar 

  97. Laitinen L. Desipramine in the treatment of Parkinson’s disease: a placebo-controlled study. Acta Neurol Scand. 1969;45:109–13.

    PubMed  CAS  Google Scholar 

  98. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23:850–7.

    PubMed  Google Scholar 

  99. Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry. 1997;9:7–13.

    PubMed  CAS  Google Scholar 

  100. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Neurology. 1997;48:1070–7.

    PubMed  CAS  Google Scholar 

  101. Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuro­pharmacol. 2007;30:201–5.

    PubMed  CAS  Google Scholar 

  102. Onofrj M, Luciano AL, Thomas A, et al. Mirtazapine induces REM sleep behavior disorder (RBD) in Parkinsonism. Neurology. 2003;60:113–5.

    PubMed  CAS  Google Scholar 

  103. The American Psychiatric Association practice guidelines: major depressive disorder. 2nd ed. http://www.psychiatryonine.com/pracGuide/pracGuideTopic_7.aspx. Accessed 1 Mar 2010.

  104. Burke WJ, Peterson J, Rubin EH. Electroconvulsive therapy in the treatment of combined depression and Parkinson’s disease. Psychosomatics. 1988;29:341–6.

    PubMed  CAS  Google Scholar 

  105. Popeo D, Kellner CH. ECT for Parkinson’s disease. Med Hypotheses. 2009;73:468–9.

    PubMed  Google Scholar 

  106. Wengel SP, Burke WJ, Pfeiffer RF, et al. Maintenance electroconvulsive therapy for intractable Parkinson’s disease. Am J Geriatr Psychiatry. 1998;6:263–9.

    PubMed  CAS  Google Scholar 

  107. Andersen K, Balldin J, Gottfries CG, et al. A double-blind evaluation of electroconvulsive therapy in Parkinson’s disease with “on-off” phenomena. Acta Neurol Scand. 1987;76:191–9.

    PubMed  CAS  Google Scholar 

  108. Shulman R. Maintenance ECT in the treatment of PD: therapy improves psychotic symptoms, physical function. Geriatrics. 2003;58:43–5.

    PubMed  Google Scholar 

  109. Aarsland D, Larsen JP, Waage O, Langeveld JH. Maintenance electroconvulsive therapy for Parkinson’s disease. Convuls Ther. 1997;13:274–7.

    PubMed  CAS  Google Scholar 

  110. Fall PA, Granerus AK. Maintenance ECT in Parkinson’s disease. J Neural Transm. 1999;106:737–41.

    PubMed  CAS  Google Scholar 

  111. Bailine S, Kremen N, Kohen I, et al. Bitemporal electroconvulsive therapy for depression in a Parkinson disease patient with a deep-brain stimulator. J ECT. 2008;24:171–2.

    PubMed  Google Scholar 

  112. Chou KL, Hurtig HI, Jaggi JL, Baltuch GH, Pelchat RJ, Weintraub D. Electroconvulsive therapy for depression in a Parkinson’s disease patient with bilateral subthalamic nucleus deep brain stimulators. Parkinsonism Relat Disord. 2005;11:403–6.

    PubMed  Google Scholar 

  113. Moscarillo FM, Annunziata CM. ECT in a patient with a deep brain stimulating electrode in place. J ECT. 2000;16:287–90.

    PubMed  CAS  Google Scholar 

  114. Rasmussen K, Abrams R. Treatment of Parkinson’s disease with electroconvulsive therapy. Psychiatr Clin North Am. 1991;14:925–33.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE, 68198-5580, USA

    Jeana L. Benton M.D., Steven P. Wengel M.D. & William J. Burke M.D.

Authors
  1. Jeana L. Benton M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven P. Wengel M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William J. Burke M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William J. Burke M.D. .

Editor information

Editors and Affiliations

  1. Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA

    Ronald F. Pfeiffer (Professor and Vice Chair) (Professor and Vice Chair)

  2. Parkinson’s Disease and Related Disorders Clinic, SUNY Downstate Medical Center, Brooklyn, NY, USA

    Ivan Bodis-Wollner

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Benton, J.L., Wengel, S.P., Burke, W.J. (2013). Depression in Parkinson’s Disease: An Update. In: Pfeiffer, R.F., Bodis-Wollner, I. (eds) Parkinson’s Disease and Nonmotor Dysfunction. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-429-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-429-6_1

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-428-9

  • Online ISBN: 978-1-60761-429-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation